Vaccines for COVID-19: Where do we stand in 2021?

被引:61
|
作者
Sharma, Ketaki [1 ,2 ]
Koirala, Archana [1 ,2 ,3 ]
Nicolopoulos, Katrina [1 ]
Chiu, Clayton [1 ,2 ]
Wood, Nicholas [1 ,2 ]
Britton, Philip N. [2 ,4 ]
机构
[1] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[3] Nepean Hosp, Dept Infect Dis, Penrith, NSW, Australia
[4] Childrens Hosp Westmead, Dept Infect Dis & Microbiol, Westmead, NSW, Australia
关键词
COVID-19; SARS-CoV-2; Vaccines; vaccines; NCOV-19; AZD1222; VACCINE; EFFICACY; BNT162B2; SCOTLAND; RISK;
D O I
10.1016/j.prrv.2021.07.001
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARSCoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity. Crown Copyright (c) 2021 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:22 / 31
页数:10
相关论文
共 50 条
  • [1] COVID-19 vaccines: Where do we stand?
    Tulay, Pinar
    Ergoren, Mahmut Cerkez
    Dundar, Munis
    EUROBIOTECH JOURNAL, 2021, 5 (01): : 13 - 16
  • [2] Deciphering Vaccines for COVID-19: where do we stand today?
    Baviskar, Tushar
    Raut, Dezaree
    Bhatt, Lokesh Kumar
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2021, 43 (01) : 8 - 21
  • [3] Myocarditis and COVID-19: Where Do We Stand?
    Jakstaite, Aiste Monika
    Papathanasiou, Maria
    Luedike, Peter
    AKTUELLE KARDIOLOGIE, 2021, 10 (01) : 27 - 31
  • [4] COVID-19 and AKI: Where Do We Stand?
    Palevsky, Paul M.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (05): : 1029 - 1032
  • [5] COVID-19 vaccines: where we stand and challenges ahead
    Forni, Guido
    Mantovani, Alberto
    CELL DEATH AND DIFFERENTIATION, 2021, 28 (02): : 626 - 639
  • [6] COVID-19 in Children: Where do we Stand?
    Nikolopoulou, Georgia B.
    Maltezou, Helena C.
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (01) : 1 - 8
  • [7] COVID-19 vaccines: where we stand and challenges ahead
    Guido Forni
    Alberto Mantovani
    Cell Death & Differentiation, 2021, 28 : 626 - 639
  • [8] Chloroquine and COVID-19, where do we stand?
    Lecuit, M.
    MEDECINE ET MALADIES INFECTIEUSES, 2020, 50 (03): : 229 - 230
  • [9] Myocarditis after RNA-based COVID-19 vaccines: Where do we stand?
    Moroni, Francesco
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 356 : 81 - 82
  • [10] Covid-19 and perioperative mortality; where do we stand?
    Shakiba, Behnam
    Irani, Shirin
    ECLINICALMEDICINE, 2020, 22